Biocon Q2 FY27 revenue growth masks shipment delays and margin pressure
Biocon reported a 52% drop in Q2 net profit to ₹41 crore despite 2% revenue growth, as $20 million in biopharma revenue was deferred due to geopolitical shipment delays. Management forecasts a stronger second half driven by biosimilars and the Q4 launch of pertuzumab in Brazil.

Biocon reported a 2% rise in quarterly revenue to ₹4,389 crore for Q2 FY27, but a 52% year-on-year plunge in consolidated net profit to ₹41 crore. The profit collapse was driven by $20 million of biopharma revenue, roughly 5% of the quarterly total, going unrecognised due to shipments delayed by geopolitical disruptions.
Managing Director Shreehas Tambe stated the delayed products reached customers after September. Accounting rules prevented revenue recognition in Q2, though the costs were booked. The shipments were completed and the revenue was recorded in October, meaning it will appear in Q3 results. "There’s no underlying business challenge. These products have subsequently been sold in the month of October itself because they reach the customers after September," Tambe said.
Margin Contraction and Profit Decline
EBITDA fell 7% to ₹865 crore, with margins contracting 200 basis points to 20%. The delayed $20 million shipment directly hit profitability. Across the company's divisions, performance was mixed for the quarter.
| Business Segment | Q2 FY27 Revenue Growth |
|---|---|
| Biosimilars | 3% |
| Generics | 10% |
| Services | -9% |
Biopharma overall revenue grew 5% to ₹3,583 crore. For the first half of the fiscal year, the picture was brighter, with a 6% rise in revenue to ₹8,725 crore and a 42% jump in net profit to ₹182 crore.
H2 Outlook Driven by Biosimilars and Brazil Launch
Management expects a stronger performance in the second half of FY27, supported by biosimilars momentum and improved profitability. Executive Chairperson Kiran Mazumdar-Shaw and her team anticipate EBITDA margins will remain in the mid-20s range.
A key near-term driver is the anticipated Q4 launch of the biosimilar pertuzumab in Brazil, following a 10-year supply partnership worth about $400 million. Supplies for the Brazilian market are expected to begin in the same quarter. The company also expects growth from its aflibercept biosimilar, Yesafili, in the second half.
Strategic Position and Market Share
Biocon has secured an agreement with Genentech for early launch dates for pertuzumab across major global markets, with a European launch also expected in Q4 in a market valued at $600-700 million. In the US, Biocon's ustekinumab biosimilar, Yesintek, holds a 34% market share.
The company continues to advance its pipeline. A second insulin fill-finish line in Malaysia is now operational. It has also technology-transferred semaglutide to its Brazilian partner Biomm and is seeking approval from Anvisa, a process that could take 12 to 24 months. On US healthcare policy, Tambe noted that the focus on affordability remains bipartisan.
Biocon's second half performance will be driven by biosimilars momentum and the Q4 launch of pertuzumab in Brazil.





